NEW LAUNCH: CarciVac®, vaccine onco BCG

28/09/2020

Bioprofarma Bagó presents CarciVac® for the treatment of non-muscle invasive bladder cancer. We are pleased to announce the launch of CarciVac® vaccine onco BCG Bacilo Calmette-Guérin. This product complements our Urology portfolio continuing our commitment to patients suffering bladder cancer.

CarciVac® is manufactured by Serum Institute of India, the world’s largest producer of vaccines, which allows us to guarantee the availability of the product in the market.

CarciVac® vaccine onco BCG Bacilo Calmette-Guérin is indicated for the treatment of:

  • Flat urothelial cell carcinoma in situ (CIS) of the bladder
  • As adjuvant treatment after TUR of primary or recurrent superficial papillary urothelial cell carcinoma (stage Ta and T1).

It is presented in a 40 mg lyophilized ampoule bottle for 3 vials.

For more information, please click here

 

NEW PRODUCT LAUNCH ANTIXAN® edaravone

Committed to our mission of providing high value-added drugs for the medical community and patients, we make available the new product ANTIXAN® edaravone for the treatment of Amyotrophic Lateral Sclerosis.

(Español) NUEVO LANZAMIENTO IBRULEU® ibrutinib

(Español) Desde Bioprofarma Bagó nos complace presentar nuestro nuevo producto IBRULEU® ibrutinib

(Español) Ateneo Hospital Pirovano

(Español) Nos complace compartirles la disertación de la Dra. Ana Acosta en el ateneo del Hospital Pirovano